Mankhwala Oletsa Menin: Chithandizo Chodabwitsa cha Khansa ya Myeloid Yoopsa
Matenda a khansa ya m'magazi (AML) ndi khansa ya m'magazi yovuta komanso yosiyana yomwe imadziwika ndi kuchulukana kwa maselo obadwa ndi matenda a m'magazi. Ngakhale kuti chithandizo chapita patsogolo, kuchiritsa AML kukupitirirabe kukhala kovuta, makamaka kwa odwala omwe ali ndi vuto la majini. Kafukufuku waposachedwa wafotokozedwa mu magaziniyi. Magazi akugogomezera kufunika kwa mankhwala oletsa Menin, kuwonetsa kuthekera kwawo kusintha chithandizo cha AML.
Udindo wa Epigenetics mu AML
Kusintha kwa epigenetic, monga DNA methylation ndi histone modification, ndi kusintha kosinthika komwe kumawongolera mawonekedwe a majini popanda kusintha DNA sequence. Kusintha kumeneku kumachita gawo lofunika kwambiri pakukula kwa AML. Kulunjika njira zosinthika za epigenetic izi kumapereka njira yatsopano yochiritsira.
Ma Histones, mapuloteni ofunikira mu DNA package, amasinthidwa pambuyo pomasulira monga acetylation ndi methylation, zomwe zimakhudza kulembedwa kwa majini. Menin, puloteni yolumikizidwa ndi jini ya MEN1, ndi yofunika kwambiri pakuwongolera epigenetic. Imagwirizana ndi histone methyltransferase KMT2A ndi anzawo ena kuti ilamulire kufotokozedwa kwa majini. Mu AML, Menin imathandizira mapulogalamu olembera khansa, makamaka kudzera mu kukweza majini a HOXA ndi MEIS1, omwe ndi ofunikira kwambiri mu KMT2A-rearranged ndi NPM1-mutated AML.
Mankhwala Oletsa Menin: Kupambana kwa Chithandizo cha AML
Ma Menin inhibitors ndi mamolekyu ang'onoang'ono osankhidwa bwino omwe adapangidwa kuti asokoneze mgwirizano pakati pa Menin ndi KMT2A, motero amaletsa njira zolembera khansa. Ma inhibitors awa awonetsa kugwira ntchito bwino kwambiri m'maphunziro asanachitike komanso azachipatala, makamaka pa KMT2A-rearranged ndi NPM1-mutated AML, zomwe pamodzi zimayimira gawo lalikulu la milandu ya AML.
Mankhwala oyamba oletsa Menin, revumenib (SNDX-5613), avomerezedwa kuti agwiritsidwe ntchito kuchipatala, ndipo ena angapo, kuphatikizapo ziftomenib (KO-539) ndi bleximenib, akuyesedwa kuchipatala. Kafukufuku wa AUGMENT-101 adawonetsa kuti revumenib idapeza kuchuluka kwa mayankho (ORR) kwa 53% mu relaxation kapena refractory (R/R) AML, yokhala ndi zotsatirapo zoyipa monga QTc prolongation and differentiation syndrome. Mofananamo, zotsatira zoyambirira kuchokera ku mayeso a KOMET-001 ndi KOMET-008 omwe amayesa ziftomenib zidawonetsa kuchuluka kwa kukhululuka komanso chitetezo.
Mankhwala ophatikizana akufufuzidwanso kuti awonjezere mphamvu ya mankhwala oletsa Menin. Kafukufuku wophatikiza revumenib ndi mankhwala ochepetsa methylation monga azacitidine ndi venetoclax wanena kuti kuchuluka kwa mayankho kumafikira 100% mwa odwala omwe ali ndi thanzi labwino komanso osakwanira AML, ngakhale kuti maphunziro ena ndi magulu akuluakulu akufunika.
Malangizo a Chitetezo ndi Tsogolo
Mankhwala oletsa Menin nthawi zambiri amakhala ndi chitetezo chabwino, ndipo zotsatirapo zake zambiri zimakhala zothazikika komanso zosinthika. Zotsatira zoyipa zomwe zimachitika nthawi zambiri zimaphatikizapo zizindikiro za m'mimba, cytopenia, ndi differentiation syndrome. Ma throughtherapy omwe US FDA imapereka kwa revumenib ndi ziftomenib akuwonetsa kufunika kwa mankhwala oletsa Menin pothana ndi zosowa zosakwaniritsidwa pa chithandizo cha AML.
Deta yodalirika ya zamankhwala yokhudza zoletsa za Menin ikuwonetsa gawo losintha pa chithandizo cha AML, zomwe zimapatsa chiyembekezo odwala omwe ali ndi majini omwe ali ndi zovuta m'mbuyomu. Pamene kafukufuku akupitilira, njirazi zikukonzekera kusintha muyezo wa chisamaliro cha AML.
Bungwe la BIOOCUS International Medical Center likudziperekabe kugwiritsa ntchito njira zamakono monga zoletsa za Menin kuti zipereke chithandizo chamakono komanso chothandiza kwa odwala padziko lonse lapansi.